despit
intens
vaccin
program
influenza
infect
remain
major
health
problem
due
virus
abil
chang
envelop
glycoprotein
hemagglutinin
ha
shift
drift
permit
influenza
escap
protect
induc
current
vaccin
natur
immun
recent
new
variant
emerg
china
caus
global
concern
first
laboratoryconfirm
human
infect
result
alarmingli
high
death
rate
second
genet
chang
found
appear
associ
enabl
avian
influenza
virus
spread
effect
mammal
thu
transmit
infect
larger
scale
current
vaccin
drug
effect
abl
target
report
rapid
develop
synthet
consensu
dna
vaccin
elicit
potent
protect
immun
virus
show
induc
broad
antibodi
respons
bind
diverg
multipl
new
member
famili
antibodi
respons
result
hightit
hai
simultan
vaccin
induc
potent
polyfunct
effector
cell
memori
respons
anim
vaccin
complet
protect
viru
infect
morbid
associ
lethal
challeng
studi
establish
synthet
consensu
dna
vaccin
repres
new
tool
target
emerg
infect
importantli
design
test
develop
seed
stock
vaccin
product
day
pandem
set
signific
implic
rapid
deploy
vaccin
protect
emerg
infecti
diseas
recent
decad
high
pathogen
avian
influenza
hpai
low
pathogen
avian
influenza
lpai
virus
caus
larg
poultri
outbreak
itali
netherland
canada
unit
kingdom
unit
state
america
mexico
viral
circul
poultri
except
outbreak
itali
virus
acquir
abil
transmit
poultri
human
caus
diseas
mortal
outbreak
highli
pathogen
influenza
viru
netherland
result
estim
human
case
one
death
newli
emerg
chines
avian
influenza
viru
one
subgroup
among
larger
group
virus
juli
th
total
laboratoryconfirm
case
peopl
die
indic
high
mortal
rate
viru
exhibit
sever
genet
featur
mammalian
influenza
virus
includ
specif
ha
protein
bind
mammalian
cellular
receptor
delet
na
stalk
associ
increas
virul
mammal
import
mutat
protein
essenti
effici
replic
avian
virus
mammalian
speci
effici
transmiss
viru
ferret
suggest
humantohuman
transmiss
viru
might
possibl
appropri
condit
result
emerg
novel
rais
concern
pandem
potenti
well
relat
influenza
virus
vaccin
current
avail
prevent
avian
influenza
infect
human
remain
urgent
need
develop
protect
vaccin
infect
new
synthet
dna
vaccin
emerg
attract
approach
variou
infecti
diseas
cancer
conceptu
dna
vaccin
mani
use
attribut
tradit
vaccin
strategi
liveattenu
vaccin
proteinpeptidebas
vaccin
dna
vaccin
shown
capabl
elicit
balanc
cell
respons
well
humor
immun
respons
smallanim
model
progress
clinic
histor
hamper
difficulti
gener
suffici
potent
cell
humor
respons
human
recent
dna
platform
use
primarili
primeboost
strategi
along
viral
vector
protein
thu
creat
inordin
long
test
develop
window
address
emerg
pandem
rapidli
order
address
technic
hurdl
associ
weak
vaccineinduc
immun
recent
appli
mani
synthet
dna
design
strategi
includ
codonrna
optim
addit
highli
effici
immunoglobulin
leader
sequenc
use
central
immunogen
broaden
immun
remov
depend
individu
viral
sequenc
new
formul
combin
highli
effici
dna
deliveri
method
vivo
electropor
ep
improv
induct
immun
respons
induc
dna
vaccin
small
anim
macaqu
recent
importantli
human
present
first
adapt
newli
develop
synthet
platform
deploy
approach
feasibl
develop
protect
vaccin
rapidli
emerg
pathogen
real
time
develop
synthet
ha
dna
vaccin
use
combin
strategi
gene
optim
dna
vaccin
deliv
ep
immunogen
evalu
mice
observ
vaccin
capabl
induc
strong
haspecif
polyfunct
effector
cell
memori
respons
addit
vaccin
abl
elicit
protect
level
hai
titer
strain
challeng
mice
lethal
dose
viru
confirm
protect
influenzadriven
mortal
rapid
develop
potenti
seed
stock
product
day
combin
improv
immun
profil
platform
support
studi
synthet
ha
vaccin
antigen
combin
electropor
deliveri
divers
emerg
pathogen
design
hemagglutinin
dna
vaccin
hemagglutinin
ha
sequenc
first
four
identifi
human
isol
retriev
global
initi
share
influenza
data
gisaid
ha
sequenc
align
use
megalign
dnastar
madison
wi
consensu
ha
sequenc
develop
codonrna
optim
subsequ
synthes
genscript
synthes
clone
express
vector
control
cytomegaloviru
immediateearli
promot
construct
name
twentyfour
primari
ha
protein
sequenc
human
viru
isol
retriev
gisaid
align
appli
phylogenet
studi
perform
use
clustal
version
phylogenet
tree
construct
base
neighborjoin
evalu
align
indirect
immunofluoresc
assay
util
confirm
gene
express
describ
previous
briefli
human
rhabdomyosarcoma
rd
cell
plate
twowel
chamber
slide
bd
bioscienc
densiti
obtain
confluenc
next
day
complet
dmem
medium
fb
gibco
allow
adher
overnight
cell
transfect
control
plasmid
ug
well
use
turbofectin
transfect
reagent
origen
accord
manufactur
instruct
fortyeight
hour
later
cell
wash
gentli
three
time
fix
slide
use
ice
cold
methanol
min
cell
incub
ha
mous
monoclon
antibodi
sino
biolog
inc
cat
dilut
room
temperatur
slide
incub
alexa
antimous
secondari
antibodi
cell
signal
technolog
min
dark
analyz
fluoresc
microscopi
leica
leica
microsystem
inc
usa
use
spot
advanc
softwar
program
spot
diagnost
instrument
inc
femal
balbc
mice
purchas
jackson
laboratori
care
accord
guidelin
nation
institut
health
univers
pennsylvania
institut
anim
care
use
committe
iacuc
mice
immun
ug
intramuscular
inject
im
quadricep
muscl
follow
vivo
electropor
ep
use
adapt
constant
current
electropor
devic
inovio
pharmaceut
inc
two
amp
constant
current
squarewav
puls
deliv
triangular
array
consist
solid
stainless
steel
electrod
puls
millisecond
length
second
delay
puls
mice
receiv
two
immun
three
week
apart
serum
sampl
collect
preimmun
two
week
second
vaccin
time
point
elisa
hemagglutin
inhibit
hai
assay
four
week
second
immun
mice
sacrif
analysi
cellular
immun
respons
measur
igg
antibodi
specif
perform
elisa
immun
control
mice
plate
coat
ashanghai
influenza
ha
protein
influenza
protein
ahangzh
protein
sino
biolog
inc
respect
standard
elisa
carri
endpoint
titer
determin
previous
describ
mathemat
formula
use
calcul
endpoint
titer
cutoff
express
standard
deviat
multipli
factor
base
number
neg
control
sera
n
confid
level
endpoint
titer
report
reciproc
last
dilut
remain
endpoint
cutoff
sera
sampl
treat
receptordestroy
enzym
rde
ratio
overnight
hour
follow
complement
inactiv
minut
start
dilut
pb
twofold
serial
dilut
rdetreat
serum
serial
dilut
vbottom
microtit
plate
four
hemagglutin
dose
ad
well
serumviru
mixtur
incub
room
temperatur
h
follow
incub
hors
red
blood
cell
cell
bovin
serum
albumin
fraction
v
salin
solut
ad
well
incub
h
room
temperatur
hai
antibodi
titer
score
reciproc
highest
dilut
exhibit
agglutin
red
blood
cell
assay
perform
duplic
mous
elispot
assay
perform
describ
previous
set
peptid
span
entir
consensu
protein
contain
amino
acid
residu
overlap
amino
acid
synthes
genscript
piscataway
nj
entir
set
peptid
pool
concentr
ugmlpeptid
pool
antigen
specif
stimul
releas
concavalin
sigmaaldrich
st
loui
mo
ugml
complet
cultur
medium
use
posit
neg
control
respect
averag
number
spot
form
cell
sfc
adjust
splenocyt
splenocyt
ad
plate
well
stimul
peptid
hour
co
presenc
protein
transport
inhibitor
cocktail
brefeldin
monensin
ebiosci
accord
manufactur
instruct
cell
stimul
cocktail
plu
protein
transport
inhibitor
phorbol
pma
ionomycin
brefeldin
monensin
ebiosci
use
posit
control
media
neg
control
cultur
use
measur
degranul
fitc
clone
biolegend
ad
time
enhanc
stain
cell
fix
stain
describ
elsewher
briefli
cell
wash
fac
buffer
pb
contain
sodium
azid
fc
surfac
stain
flourochromeconjug
antibodi
cell
wash
fac
buffer
fixat
permeabil
use
bd
bd
san
diego
ca
usa
accord
manufactur
protocol
follow
intracellular
stain
follow
antibodi
use
surfac
stain
livedead
fixabl
violet
dead
cell
stain
kit
invitrogen
clone
bd
bioscienc
clone
bd
bioscienc
petexasr
clone
abcam
clone
biolegend
intracellular
stain
follow
antibodi
use
apc
clone
biolegend
pe
clone
ebiosci
clone
ebiosci
clone
biolegend
data
collect
use
lsrii
flow
cytomet
bd
bioscienc
analyz
use
flowjo
softwar
tree
star
ashland
spice
free
avail
http
exonniaidnihgovspic
boolean
gate
perform
use
flowjo
softwar
examin
polyfunction
cell
vaccin
anim
flow
cytometri
cell
gate
singlet
use
fsch
fsca
follow
gate
livedead
dump
channel
cell
examin
tcell
popul
twenti
femal
balbc
mice
divid
two
group
immun
group
mice
immun
group
immun
twice
three
week
apart
four
week
second
immun
mice
anesthet
isofluran
subsequ
challeng
intranas
administr
bolu
deliveri
nostril
use
standard
micropipett
ld
influenza
viru
dulbecco
modifi
eagl
medium
dmem
plu
fetal
bovin
serum
fb
challeng
anim
weigh
daili
day
monitor
clinic
sign
influenza
infect
use
approv
score
sheet
surviv
anim
monitor
total
day
procedur
score
method
approv
institut
anim
care
committe
nation
microbiolog
laboratori
nml
public
health
agenc
canada
phac
accord
guidelin
canadian
council
anim
care
infecti
work
perform
biosafeti
level
facil
standard
pair
student
ttest
appli
analyz
statist
signific
quantit
data
produc
studi
p
consid
statist
signific
ha
consensu
sequenc
gener
first
four
ha
sequenc
isol
human
publish
gisaid
global
initi
share
influenza
data
phylogenet
analysi
indic
sequenc
ident
two
ha
protein
human
isol
could
low
ident
consensu
ha
primari
ha
protein
consensu
approach
antigen
develop
influenza
therefor
depend
upon
one
viral
isol
may
repres
total
pandem
real
time
relev
placement
consensu
ha
sequenc
indic
fig
gener
consensu
ha
sequenc
codon
rna
optim
perform
previous
describ
synthet
gene
bp
length
synthes
sequenc
verifi
subclon
express
vector
bamhi
noti
site
name
fig
day
determin
express
construct
indirect
immunofluoresc
assay
carri
use
ha
mous
monoclon
antibodi
high
membran
express
observ
fluoresc
microscopi
cell
fig
support
idea
express
ha
protein
surfac
protein
protein
exhibit
rel
nativ
conform
control
express
detect
null
vector
transfect
cell
upon
confirm
express
construct
first
investig
whether
immunogen
capabl
drive
crossreact
antibodi
respons
mice
immun
twice
three
week
apart
serum
sampl
collect
prevaccin
two
week
post
second
immun
util
elisa
assay
shown
fig
abl
detect
hightit
vaccineinduc
antibodi
respons
three
differ
ha
protein
immun
mice
averag
haspecif
antibodi
endpoint
titer
ha
rang
rang
rang
respect
fig
data
indic
vaccin
elicit
strong
broad
antibodi
respons
order
test
whether
crossreact
antibodi
may
protect
next
employ
standard
hemagglutin
inhibit
assay
hai
test
abil
plasmid
gener
function
antibodi
hai
activ
due
time
emerg
strain
anim
experi
strain
quantifi
resourc
lab
avail
test
accordingli
use
determin
serum
hai
antibodi
titer
induc
vaccin
depict
fig
two
week
two
immun
induc
protect
hai
titer
everi
immun
anim
gmt
titer
mice
suggest
cell
mediat
immun
crucial
viru
clearanc
number
secret
cell
correl
efficaci
live
attenu
influenza
vaccin
children
therefor
confirm
elicit
protect
antibodi
respons
explor
abil
induc
antigenspecif
cellular
immun
respons
mice
immun
twice
sacrif
four
week
post
second
immun
fig
elispot
assay
perform
shown
fig
averag
respons
four
pool
overlap
peptid
mice
immun
splenocyt
minim
background
spot
observ
mice
clearli
strong
respons
induc
vaccin
subsequ
character
phenotyp
cytokin
profil
product
memori
cell
gener
herein
studi
longev
qualiti
effector
cell
memori
induc
dna
vaccin
four
week
last
vaccin
mice
sacrif
splenocyt
stimul
vitro
pool
peptid
product
cell
analyz
dna
vaccin
elicit
signific
haspecif
cell
produc
three
cytokin
fig
signific
number
cell
doubl
posit
tripleposit
fig
tripl
posit
doubl
posit
cell
phenotyp
normal
repres
effector
memori
central
memori
cell
indic
induct
memori
like
cell
immun
respons
ha
vaccin
term
cell
found
vaccin
elicit
substanti
higher
frequenc
haspecif
cell
total
splenic
cell
fig
produc
either
alon
dual
tripl
fig
character
vaccineinduc
cell
next
analyz
cytotox
potenti
induc
cell
undergo
degranul
therefor
cultur
stain
antibodi
marker
degranul
observ
cell
vaccin
mice
show
signific
increas
antigenspecif
degranul
compar
mice
result
indic
vaccin
potent
abil
induc
cytolyt
cell
respons
potenti
abil
clear
influenza
infect
cell
addit
vaccin
also
induc
high
frequenc
produc
haspecif
cell
modest
signific
increas
respons
respect
compar
group
fig
interestingli
proport
order
effector
cell
subpopul
respons
ha
stimul
similar
greater
high
frequenc
effector
cell
secret
among
haspecif
cell
popul
indic
strong
vaccin
potenc
induc
vaccin
fig
overal
frequenc
hierarchi
effector
memori
cell
express
one
combin
two
three
cytokin
flow
cytometri
taken
togeth
observ
strong
effector
memori
cell
well
protect
antibodi
respons
induc
vaccin
approach
magnitud
cell
respons
similar
induc
viral
infect
rather
weak
respons
gener
tradit
dna
immun
determin
vaccin
could
elicit
protect
immun
lethal
viral
challeng
mice
immun
twice
three
week
apart
challeng
lethal
dose
viru
four
week
post
final
immun
monitor
weight
loss
day
fig
accord
protocol
establish
prior
studi
anim
fall
threshold
initi
bodi
weight
human
euthan
shown
fig
group
one
mous
lost
bodi
weight
day
postchalleng
five
mice
exhibit
weight
loss
day
postchalleng
rest
four
mice
lost
bodi
weight
day
contrast
vaccin
mice
surviv
day
post
challeng
observ
pathogen
effect
weight
loss
time
studi
end
data
support
synthet
dna
vaccineinduc
immun
respons
could
protect
influenza
infect
emerg
deadli
influenza
viru
eastern
china
invok
question
origin
influenza
pandem
risk
human
avian
influenza
virus
potenti
abil
infect
human
stabli
transmit
human
current
situat
entir
popul
risk
potenti
sever
pandem
great
concern
studi
detail
rapid
develop
synthet
ha
dna
vaccin
effici
deliv
vivo
ep
capabl
elicit
strong
effector
cell
memori
respons
also
broadli
reactiv
antibodi
respons
importantli
confirm
immun
dna
vaccin
induc
protect
hai
titer
immun
anim
result
protect
mortal
morbid
due
influenza
infect
date
first
report
demonstr
ha
dna
vaccin
protect
newli
emerg
influenza
subtyp
current
vaccin
platform
requir
signific
develop
product
timelin
address
pandem
given
mortal
rate
potenti
infect
larg
number
human
import
develop
strategi
thwart
potenti
grow
pandem
ideal
influenza
vaccin
platform
rapid
deploy
includ
technolog
rapidli
straightforwardli
util
design
effect
vaccin
multipl
known
new
strain
deliveri
mechan
quickli
induc
cellular
humor
immun
respons
new
antigen
human
approach
rapid
design
scale
mass
product
relev
clinic
track
record
approach
stabl
distribut
purpos
show
enhanc
dna
approach
exhibit
properti
use
pandem
demonstr
platform
comput
immunogen
design
immunogen
hand
anim
studi
short
day
pandem
set
immun
data
avail
three
week
receipt
seed
stock
gener
day
without
amplif
select
requir
thu
limit
potenti
mutat
induc
process
immunogen
develop
distribut
product
begin
earli
day
post
pathogen
detect
use
approach
million
dose
could
produc
scale
within
month
identif
pathogen
addit
stabil
dna
lack
requir
viral
amplif
step
ensur
fidel
process
furthermor
grow
safeti
record
dna
clinic
adult
elderli
children
import
suggest
potenti
improv
potenc
platform
surfac
ha
protein
influenza
viru
contain
two
structur
element
head
stalk
differ
potenti
util
vaccin
target
antibodi
target
area
ha
globular
head
region
drive
hai
activ
viral
neutral
studi
due
limit
avail
viru
strain
test
hai
titer
howev
hightit
crossreact
bind
antibodi
aanhui
region
confirm
vaccin
mice
high
titer
bind
also
observ
therefor
vaccin
dna
vaccin
appear
induc
broadli
reactiv
antibodi
multipl
strain
effort
perform
addit
hai
assay
viru
strain
ongo
stock
becom
avail
howev
past
research
influenza
model
system
data
present
vaccin
appear
breath
hai
would
similar
hai
antibodi
major
correl
protect
flu
vaccin
although
immun
mice
exhibit
greater
protect
hai
titer
studi
older
design
dna
vaccin
gener
elicit
workabl
level
antibodi
human
recent
use
similar
combin
approach
gene
optim
deliveri
success
demonstr
human
subject
immun
novel
hpv
dna
vaccin
could
induc
strong
de
novo
antihpv
antibodi
respons
antibodi
titer
remain
high
even
month
last
immun
strong
longlast
antibodi
measur
clinic
studi
encourag
develop
hai
antibodi
depend
influenza
dna
vaccin
furthermor
studi
suggest
potenti
human
dose
could
rang
mg
per
immun
cellular
immun
respons
play
import
role
influenza
viru
infect
mani
studi
shown
cell
induc
follow
infect
influenza
viru
play
critic
role
rapid
clearanc
influenza
viru
thu
limit
pathogenesi
cell
also
induc
follow
influenza
viru
infect
play
role
maintain
cell
memori
respons
provid
help
b
cell
rapid
antibodi
product
previou
studi
identifi
cell
cell
epitop
within
ha
antigen
epitop
shown
confer
protect
human
current
studi
show
could
induc
potent
polyfunct
effector
cell
memori
respons
percentag
antigenspecif
cell
secret
increas
significantli
indic
potenti
abil
vaccin
induc
cytolyt
cell
respons
clear
influenza
infect
cell
data
support
idea
synthet
vaccin
could
induc
antigenspecif
antibodi
cell
respons
would
import
protect
pandem
herein
report
develop
highli
potent
synthet
ha
dna
vaccin
combin
adapt
constant
current
electropor
deliveri
platform
capabl
elicit
robust
cellular
immun
respons
broadli
crossreact
antibodi
respons
gener
complet
protect
lethal
challeng
week
develop
vaccin
regim
potent
synthet
dna
vaccin
platform
elimin
mani
hurdl
limit
rapid
develop
deploy
vaccin
emerg
pandem
lack
requir
recombin
vivo
product
recent
compet
technolog
quicken
product
time
line
well
elimin
major
potenti
sourc
error
seed
develop
new
product
method
dna
shorten
product
timelin
platform
exhibit
grow
safeti
record
clinic
studi
new
platform
develop
vaccin
combat
pandem
infect
includ
influenza
warrant
cytokin
frequenc
phenotyp
profil
specif
cell
immun
cytokin
recal
respons
ha
measur
week
last
immun
ic
flow
cytometri
cell
identifi
express
gate
percentag
total
cell
express
respons
ha
stimul
b
averag
percentag
haspecif
doublepositiveproduc
cell
c
multiparamet
flow
cytometri
use
determin
percentag
multifunct
cell
cytokin
profil
bar
chart
show
percentag
specif
cell
display
tripl
doubl
singl
posit
cell
pie
chart
show
rel
proport
cytokin
subpopul
ha
stimul
background
stain
cell
stimul
medium
alon
subtract
data
repres
five
mice
per
group
p
p
p
use
student
ttest
figur
cytokin
frequenc
phenotyp
profil
specif
cell
immun
cytokin
frequenc
phenotyp
profil
specif
cell
immun
cytokin
recal
respons
ha
measur
week
last
immun
ic
flow
cytometri
cell
identifi
express
gate
percentag
total
cell
express
respons
ha
stimul
b
averag
percentag
haspecif
doublepositiveproduc
cell
c
multiparamet
flow
cytometri
use
determin
percentag
multifunct
cell
cytokin
profil
bar
chart
show
percentag
specif
cell
display
tripl
doubl
singl
posit
cell
pie
chart
show
rel
proport
cytokin
subpopul
ha
stimul
antigenspecif
cytolyt
degranul
cell
measur
degranul
marker
express
background
stain
cell
stimul
medium
alon
subtract
data
repres
five
mice
per
group
p
p
p
use
student
ttest
